Kamada (NASDAQ:KMDA) updates on its development of a plasma-derived immunoglobulin (IgG) product for COVID-19.
The company completed manufacturing of the first
batch of its plasma-derived IgG product for COVID-19 and additional
production is ongoing. The initial vials are available for compassionate
use in Israel.
Kamada intends to initiate a Phase 1/2 clinical study in hospitalized COVID-19 patients in Israel during Q3.
In order to expand its clinical development
program to the U.S., Kamada and its partner Kedrion Biopharma, intends
to conduct a pre-IND meeting with the FDA early in Q3.
Kedrion is currently collecting COVID-19
convalescent plasma from U.S. recovered patients to manufacture
additional batches of the product.
https://seekingalpha.com/news/3583716-kamada-antibody-therapy-okd-for-compassionate-use-in-israel-for-covidminus-19
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.